5 days ago
1
Grandbrothers/iStock Editorial via Getty Images
Aquestive Therapeutics (NASDAQ:AQST) added ~15% in the premarket on Thursday after announcing that the U.S. FDA has informed it that an advisory committee meeting will not be necessary in the review of its allergy therapy, Anaphylm.
The Warren, New Jersey-based company
English (US) ·